Skip to contentB
Bone Biologics Corp
B
BBLGBone Biologics Corp Q1 2023 · 10-Q
Revenue—
Net Income-$3.71M-$3.71MN/M vs Q1 2022 EPS Diluted-$55.20-$55.20no prior Q1 2022 on file Operating Income-$3,147,537N/M Operating Cash Flow-$1,349,993N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bone Biologics Corp · CIK 1419554 · Engraved from SEC EDGAR
ended Mar 31, 2023 · filed May 15, 2023 · 45 d after period end